(CLBT) Cellebrite DI - Overview
Exchange: NASDAQ •
Country: Israel •
Currency: USD •
Type: Common Stock •
ISIN: IL0011794802
Stock: Digital Forensics, Extraction, Analysis, Case Management, Training
Total Rating 28
Risk 61
Buy Signal -1.41
| Risk 5d forecast | |
|---|---|
| Volatility | 46.7% |
| Relative Tail Risk | -11.5% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.70 |
| Alpha | -43.27 |
| Character TTM | |
|---|---|
| Beta | 0.782 |
| Beta Downside | 0.553 |
| Drawdowns 3y | |
|---|---|
| Max DD | 48.00% |
| CAGR/Max DD | 0.69 |
EPS (Earnings per Share)
Revenue
Description: CLBT Cellebrite DI January 11, 2026
Cellebrite DI Ltd. (NASDAQ: CLBT) builds software platforms that enable legally sanctioned investigations across the globe, covering the full forensic lifecycle-from data acquisition and decoding to analysis, visualization, and case management. Its flagship products include Inseyets for evidence collection, Pathfinder for automated analysis, Smart Search for open-source intelligence, and Guardian for evidence management, with enterprise-focused extensions such as Endpoint Inspector and Endpoint Mobile Now.
In FY 2023 the company reported revenue of roughly $210 million, a year-over-year increase of about 15%, and an operating margin near 18%, reflecting strong demand from law-enforcement agencies and corporate security units. The digital-forensics market is expanding at a compound annual growth rate of 12-14% driven by rising cyber-crime incidents, stricter data-privacy regulations, and increasing budgets for investigative technology in both the public and private sectors.
For a deeper quantitative comparison, you might explore ValueRay’s analyst toolkit to benchmark Cellebrite’s performance against peers.
Piotroski VR‑10 (Strict, 0-10) 5.5
| Net Income: 78.3m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.17 > 0.02 and ΔFCF/TA -0.53 > 1.0 |
| NWC/Revenue: 43.35% < 20% (prev 67.82%; Δ -24.47% < -1%) |
| CFO/TA 0.18 > 3% & CFO 173.5m > Net Income 78.3m |
| Net Debt (-101.8m) to EBITDA (83.6m): -1.22 < 3 |
| Current Ratio: 1.56 > 1.5 & < 3 |
| Outstanding Shares: last quarter (251.5m) vs 12m ago 1.68% < -2% |
| Gross Margin: 84.20% > 18% (prev 0.84%; Δ 8335 % > 0.5%) |
| Asset Turnover: 58.39% > 50% (prev 58.10%; Δ 0.29% > 0%) |
| Interest Coverage Ratio: -3.80 > 6 (EBITDA TTM 83.6m / Interest Expense TTM -18.9m) |
Altman Z'' 1.54
| A: 0.22 (Total Current Assets 575.9m - Total Current Liabilities 369.7m) / Total Assets 938.9m |
| B: -0.09 (Retained Earnings -86.5m / Total Assets 938.9m) |
| C: 0.09 (EBIT TTM 71.8m / Avg Total Assets 814.7m) |
| D: -0.19 (Book Value of Equity -84.3m / Total Liabilities 454.5m) |
| Altman-Z'' Score: 1.54 = BB |
Beneish M -2.04
| DSRI: 1.08 (Receivables 105.0m/82.4m, Revenue 475.7m/401.2m) |
| GMI: 1.00 (GM 84.20% / 84.40%) |
| AQI: 2.50 (AQ_t 0.35 / AQ_t-1 0.14) |
| SGI: 1.19 (Revenue 475.7m / 401.2m) |
| TATA: -0.10 (NI 78.3m - CFO 173.5m) / TA 938.9m) |
| Beneish M-Score: -2.04 (Cap -4..+1) = BB |
What is the price of CLBT shares?
As of February 19, 2026, the stock is trading at USD 14.04 with a total of 1,790,444 shares traded.
Over the past week, the price has changed by -1.54%, over one month by -14.29%, over three months by -23.28% and over the past year by -30.80%.
Over the past week, the price has changed by -1.54%, over one month by -14.29%, over three months by -23.28% and over the past year by -30.80%.
Is CLBT a buy, sell or hold?
Cellebrite DI has received a consensus analysts rating of 4.75.
Therefore, it is recommended to buy CLBT.
- StrongBuy: 6
- Buy: 2
- Hold: 0
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the CLBT price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 21.7 | 54.3% |
| Analysts Target Price | 21.7 | 54.3% |
CLBT Fundamental Data Overview February 18, 2026
P/E Trailing = 47.2258
P/E Forward = 36.63
P/S = 7.5241
P/B = 7.405
Revenue TTM = 475.7m USD
EBIT TTM = 71.8m USD
EBITDA TTM = 83.6m USD
Long Term Debt = 18.7m USD (estimated: total debt 22.7m - short term 4.00m)
Short Term Debt = 4.00m USD (from shortTermDebt, last quarter)
Debt = 22.7m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -101.8m USD (from netDebt column, last quarter)
Enterprise Value = 3.16b USD (3.58b + Debt 22.7m - CCE 437.1m)
Interest Coverage Ratio = -3.80 (Ebit TTM 71.8m / Interest Expense TTM -18.9m)
EV/FCF = 19.74x (Enterprise Value 3.16b / FCF TTM 160.3m)
FCF Yield = 5.07% (FCF TTM 160.3m / Enterprise Value 3.16b)
FCF Margin = 33.70% (FCF TTM 160.3m / Revenue TTM 475.7m)
Net Margin = 16.47% (Net Income TTM 78.3m / Revenue TTM 475.7m)
Gross Margin = 84.20% ((Revenue TTM 475.7m - Cost of Revenue TTM 75.2m) / Revenue TTM)
Gross Margin QoQ = 84.71% (prev 83.88%)
Tobins Q-Ratio = 3.37 (Enterprise Value 3.16b / Total Assets 938.9m)
Interest Expense / Debt = 5.95% (Interest Expense 1.35m / Debt 22.7m)
Taxrate = 19.07% (5.01m / 26.3m)
NOPAT = 58.1m (EBIT 71.8m * (1 - 19.07%))
Current Ratio = 1.56 (Total Current Assets 575.9m / Total Current Liabilities 369.7m)
Debt / Equity = 0.05 (Debt 22.7m / totalStockholderEquity, last quarter 484.3m)
Debt / EBITDA = -1.22 (Net Debt -101.8m / EBITDA 83.6m)
Debt / FCF = -0.63 (Net Debt -101.8m / FCF TTM 160.3m)
Total Stockholder Equity = 426.0m (last 4 quarters mean from totalStockholderEquity)
RoA = 9.61% (Net Income 78.3m / Total Assets 938.9m)
RoE = 18.39% (Net Income TTM 78.3m / Total Stockholder Equity 426.0m)
RoCE = 16.14% (EBIT 71.8m / Capital Employed (Equity 426.0m + L.T.Debt 18.7m))
RoIC = 14.29% (NOPAT 58.1m / Invested Capital 406.5m)
WACC = 8.77% (E(3.58b)/V(3.60b) * Re(8.80%) + D(22.7m)/V(3.60b) * Rd(5.95%) * (1-Tc(0.19)))
Discount Rate = 8.80% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 13.73%
[DCF Debug] Terminal Value 78.78% ; FCFF base≈144.8m ; Y1≈178.6m ; Y5≈304.2m
Fair Price DCF = 18.59 (EV 4.44b - Net Debt -101.8m = Equity 4.54b / Shares 244.5m; r=8.77% [WACC]; 5y FCF grow 25.0% → 2.90% )
EPS Correlation: 57.85 | EPS CAGR: 74.11% | SUE: -0.43 | # QB: 0
Revenue Correlation: 98.70 | Revenue CAGR: 21.33% | SUE: 0.99 | # QB: 2
EPS next Quarter (2026-03-31): EPS=0.10 | Chg30d=-0.010 | Revisions Net=-3 | Analysts=6
EPS current Year (2026-12-31): EPS=0.55 | Chg30d=+0.004 | Revisions Net=+0 | Growth EPS=+8.2% | Growth Revenue=+19.5%
EPS next Year (2027-12-31): EPS=0.65 | Chg30d=+0.012 | Revisions Net=+1 | Growth EPS=+17.4% | Growth Revenue=+17.0%
P/E Forward = 36.63
P/S = 7.5241
P/B = 7.405
Revenue TTM = 475.7m USD
EBIT TTM = 71.8m USD
EBITDA TTM = 83.6m USD
Long Term Debt = 18.7m USD (estimated: total debt 22.7m - short term 4.00m)
Short Term Debt = 4.00m USD (from shortTermDebt, last quarter)
Debt = 22.7m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -101.8m USD (from netDebt column, last quarter)
Enterprise Value = 3.16b USD (3.58b + Debt 22.7m - CCE 437.1m)
Interest Coverage Ratio = -3.80 (Ebit TTM 71.8m / Interest Expense TTM -18.9m)
EV/FCF = 19.74x (Enterprise Value 3.16b / FCF TTM 160.3m)
FCF Yield = 5.07% (FCF TTM 160.3m / Enterprise Value 3.16b)
FCF Margin = 33.70% (FCF TTM 160.3m / Revenue TTM 475.7m)
Net Margin = 16.47% (Net Income TTM 78.3m / Revenue TTM 475.7m)
Gross Margin = 84.20% ((Revenue TTM 475.7m - Cost of Revenue TTM 75.2m) / Revenue TTM)
Gross Margin QoQ = 84.71% (prev 83.88%)
Tobins Q-Ratio = 3.37 (Enterprise Value 3.16b / Total Assets 938.9m)
Interest Expense / Debt = 5.95% (Interest Expense 1.35m / Debt 22.7m)
Taxrate = 19.07% (5.01m / 26.3m)
NOPAT = 58.1m (EBIT 71.8m * (1 - 19.07%))
Current Ratio = 1.56 (Total Current Assets 575.9m / Total Current Liabilities 369.7m)
Debt / Equity = 0.05 (Debt 22.7m / totalStockholderEquity, last quarter 484.3m)
Debt / EBITDA = -1.22 (Net Debt -101.8m / EBITDA 83.6m)
Debt / FCF = -0.63 (Net Debt -101.8m / FCF TTM 160.3m)
Total Stockholder Equity = 426.0m (last 4 quarters mean from totalStockholderEquity)
RoA = 9.61% (Net Income 78.3m / Total Assets 938.9m)
RoE = 18.39% (Net Income TTM 78.3m / Total Stockholder Equity 426.0m)
RoCE = 16.14% (EBIT 71.8m / Capital Employed (Equity 426.0m + L.T.Debt 18.7m))
RoIC = 14.29% (NOPAT 58.1m / Invested Capital 406.5m)
WACC = 8.77% (E(3.58b)/V(3.60b) * Re(8.80%) + D(22.7m)/V(3.60b) * Rd(5.95%) * (1-Tc(0.19)))
Discount Rate = 8.80% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 13.73%
[DCF Debug] Terminal Value 78.78% ; FCFF base≈144.8m ; Y1≈178.6m ; Y5≈304.2m
Fair Price DCF = 18.59 (EV 4.44b - Net Debt -101.8m = Equity 4.54b / Shares 244.5m; r=8.77% [WACC]; 5y FCF grow 25.0% → 2.90% )
EPS Correlation: 57.85 | EPS CAGR: 74.11% | SUE: -0.43 | # QB: 0
Revenue Correlation: 98.70 | Revenue CAGR: 21.33% | SUE: 0.99 | # QB: 2
EPS next Quarter (2026-03-31): EPS=0.10 | Chg30d=-0.010 | Revisions Net=-3 | Analysts=6
EPS current Year (2026-12-31): EPS=0.55 | Chg30d=+0.004 | Revisions Net=+0 | Growth EPS=+8.2% | Growth Revenue=+19.5%
EPS next Year (2027-12-31): EPS=0.65 | Chg30d=+0.012 | Revisions Net=+1 | Growth EPS=+17.4% | Growth Revenue=+17.0%